Virax Biolabs Group Limited Ordinary Shares (NASDAQ:VRAX) — Market Cap & Net Worth
Market Cap & Net Worth: Virax Biolabs Group Limited Ordinary Shares (VRAX)
Virax Biolabs Group Limited Ordinary Shares (NASDAQ:VRAX) has a market capitalization of $978.41K ($978.41K) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30218 globally and #5872 in its home market, demonstrating a -17.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Virax Biolabs Group Limited Ordinary Shares's stock price $0.13 by its total outstanding shares 7423432 (7.42 Million). Analyse Virax Biolabs Group Limited Ordinary Sha operating cash flow efficiency to see how efficiently the company converts income to cash.
Virax Biolabs Group Limited Ordinary Shares Market Cap History: 2022 to 2026
Virax Biolabs Group Limited Ordinary Shares's market capitalization history from 2022 to 2026. Data shows change from $54.19 Million to $978.41K (-85.23% CAGR).
Index Memberships
Virax Biolabs Group Limited Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #905 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2870 of 3165 |
Weight: Virax Biolabs Group Limited Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Virax Biolabs Group Limited Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Virax Biolabs Group Limited Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
405.47x
Virax Biolabs Group Limited Ordinary Shares's market cap is 405.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $10.84 Million | $8.56K | -$5.46 Million | 1266.00x | N/A |
| 2024 | $16.70 Million | $156.42K | -$6.73 Million | 106.78x | N/A |
| 2025 | $2.57 Million | $6.33K | -$6.06 Million | 405.47x | N/A |
Competitor Companies of VRAX by Market Capitalization
Companies near Virax Biolabs Group Limited Ordinary Shares in the global market cap rankings as of May 4, 2026.
Key companies related to Virax Biolabs Group Limited Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Virax Biolabs Group Limited Ordinary Shares Historical Marketcap From 2022 to 2026
Between 2022 and today, Virax Biolabs Group Limited Ordinary Shares's market cap moved from $54.19 Million to $ 978.41K, with a yearly change of -85.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $978.41K | -61.89% |
| 2025 | $2.57 Million | -84.63% |
| 2024 | $16.70 Million | +54.11% |
| 2023 | $10.84 Million | -80.00% |
| 2022 | $54.19 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Virax Biolabs Group Limited Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $978.41K USD |
| MoneyControl | $978.41K USD |
| MarketWatch | $978.41K USD |
| marketcap.company | $978.41K USD |
| Reuters | $978.41K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more